Faes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
According to Faes Farma, S.A.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 10.66. At the end of 2022 the company had a P/E ratio of 11.99.
Year | P/E ratio |
---|---|
2023 | 10.66 |
2022 | 11.99 |
2021 | 12.31 |
2020 | 13.46 |
2019 | 21.36 |
2018 | 15.31 |
2017 | 18.09 |
2016 | 23.10 |
2015 | 22.88 |
2014 | 16.31 |
2013 | 26.18 |
2012 | 17.36 |
2011 | 17.59 |
2010 | 25.73 |
2009 | 32.94 |
2008 | 18.68 |
2007 | 44.95 |
2006 | 88.59 |
2005 | 48.44 |
2004 | 72.73 |
2003 | 83.51 |